SAN DIEGO - illiNews -- Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded an advanced research and development contract for $16.5 million with options for an additional $30.0 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) to advance MBP091 though the completion of a Phase 1 clinical trial.
MBP091 is a single human monoclonal antibody (mAb) that is being developed as a pan-Marburg virus therapeutic for the treatment of hemorrhagic fevers caused by Marburg and the closely related Ravn virus. The mAb was isolated in the laboratory of Dr. James Crowe at Vanderbilt University Medical Center from a survivor or Marburg virus infection and subsequently licensed by Mapp. MBP091 has been evaluated in numerous preclinical experiments and has demonstrated the ability to neutralize Marburg virus in vitro and protect from lethal challenge of Marburg in vivo.
Marburg virus is a member of the filovirus family and causes a hemorrhagic fever similar to that caused by Ebola. First identified in 1967, Marburg virus has caused numerous outbreaks, even as recently as 2017 in Uganda, with relatively high mortality rates. "The award of this contract by BARDA will allow Mapp to advance the development of MBP091 to first in human evaluation with the ultimate goal of making this medical countermeasure available to victims of Marburg virus," said Dr. Ronald Aimes, Vice President of Nonclinical Development at Mapp and the Principal Investigator on this contract.
More on illi News
"We are pleased to continue and expand our productive relationship with BARDA, which represents a good example of a public-private partnership that advances much needed therapeutics for infected individuals and the Strategic National Stockpile," said Dr. Kevin J. Whaley, Chief Executive Officer.
###
About Mapp Biopharmaceutical: Mapp Biopharmaceutical was founded in 2003 to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. www.mappbio.com
This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract Nos. HHSO100201900018C and HHSO100201700023C, a National Institute of Health grant No. 2SB1 AI082744 and Medical CBRN Defense Consortium Base Agreement 2018-843 under OTA W15QKN-16-9-1002.
MBP091 is a single human monoclonal antibody (mAb) that is being developed as a pan-Marburg virus therapeutic for the treatment of hemorrhagic fevers caused by Marburg and the closely related Ravn virus. The mAb was isolated in the laboratory of Dr. James Crowe at Vanderbilt University Medical Center from a survivor or Marburg virus infection and subsequently licensed by Mapp. MBP091 has been evaluated in numerous preclinical experiments and has demonstrated the ability to neutralize Marburg virus in vitro and protect from lethal challenge of Marburg in vivo.
Marburg virus is a member of the filovirus family and causes a hemorrhagic fever similar to that caused by Ebola. First identified in 1967, Marburg virus has caused numerous outbreaks, even as recently as 2017 in Uganda, with relatively high mortality rates. "The award of this contract by BARDA will allow Mapp to advance the development of MBP091 to first in human evaluation with the ultimate goal of making this medical countermeasure available to victims of Marburg virus," said Dr. Ronald Aimes, Vice President of Nonclinical Development at Mapp and the Principal Investigator on this contract.
More on illi News
- National ATM Council Announces Debbi Haacke as Vice-Chair of NAC Governmental Affairs Committee
- Aura Alliance Partners with InfoPlus
- Experience Nature & Samurai Culture, Early Autumn in Nikko and Aizu, Japan
- Larrys Diner Offers Outdoor Dining in Plainfield
- New Website for Larrys Restaurant in Plainfield IL
"We are pleased to continue and expand our productive relationship with BARDA, which represents a good example of a public-private partnership that advances much needed therapeutics for infected individuals and the Strategic National Stockpile," said Dr. Kevin J. Whaley, Chief Executive Officer.
###
About Mapp Biopharmaceutical: Mapp Biopharmaceutical was founded in 2003 to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. www.mappbio.com
This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract Nos. HHSO100201900018C and HHSO100201700023C, a National Institute of Health grant No. 2SB1 AI082744 and Medical CBRN Defense Consortium Base Agreement 2018-843 under OTA W15QKN-16-9-1002.
Source: Mapp Biopharmaceutical, Inc.
Filed Under: Medical, Government
0 Comments
Latest on illi News
- DMS CEO Joe Marinucci Named 2019 E&Y Entrepreneur Of The Year
- Recording Artist, T-Roc Releases New EP 'The International Party'
- Francis Bacon Makes Comeback as Shakespeare Authorship Candidate
- North Center Housing Market Heads for Higher Ground in May Boosted by 65% Increase in Attached Sales
- Charles Nowicki of World Wide Land Transfer, Inc. Elected PLTA President
- 90 Days to a Glass Half Full Lifestyle Book by Chris Edwards Napa Available on Amazon
- Las Vegas Walk of Stars Postpones their 88th Star Ceremony for Make-A-Wish Creator Frank Shankwitz
- York Solutions Wins Best and Brightest Companies to Work For® in Chicago
- Going with the flow: Kraft-Sussman brings new eco-friendly cremation option to Nevada viewed as gentler on the deceased
- 'Effing Simple' author gets practical about business advice
- OSHA Cites Metal Extraction Facility After Arc Flash
- Regency DRT/DKI awarded prestigious Phoenix Award
- Chicago: Mayor Lightfoot Announces Reforms to Workers' Compensation Program
- Chicago gets its first-ever Digital Marketing Financial Summit in Chicago
- Password RBL adds Pwned Passwords database to their password blacklisting service
- A Blockbuster Ruling In Child Abuse Cases
- Lantek and BCAM collaborate to revolutionize part nesting calculation for sheet metal cutting
- Summer Fun Awaits On the 28th Annual Michigander Bicycle Tour
- Finding Real Love in The Age of The "Me Too" Movement
- Various Measures Introduced to and Approved by the Chicago City Council